Washington Growth Strategies’s AbbVie ABBV Stock Holding History

Washington Growth Strategies’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Hold	4,299	–	–	0.6%	30
2026 Q1	$935K	Hold	4,299	–	–	0.61%	31
2025 Q4	$982K	Hold	4,299	–	–	0.64%	31
2025 Q3	$995K	Hold	4,299	–	–	0.71%	26
2025 Q2	$798K	Buy	4,299 +4,089	+1,947%	+$760K	0.61%	28
2025 Q1	$621	Buy	+210	New	+$40.8K	0.56%	26
2024 Q3	$2.96K	Buy	+575	New	+$107K	0.11%	35

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Washington Growth Strategies's ABBV Position: Q2 2026 in Review

Washington Growth Strategies held its AbbVie (ABBV) position steady in Q2 2026 at 4,299 shares worth $1.08M. The position accounts for 0.6% of the portfolio, ranked #30.

Washington Growth Strategies first reported a position in ABBV in Q3 2024 and has held it in 7 quarters since. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Washington Growth Strategies held 4,299 shares of AbbVie worth $1.08M as of Q2 2026.
Washington Growth Strategies left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.6% of Washington Growth Strategies's portfolio in Q2 2026, its #30 holding.
Washington Growth Strategies first reported a position in AbbVie in Q3 2024 and has held it in 7 quarters since.
4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Washington Growth Strategies's 13F filing for Q2 2026, filed 16 Jul 2026.